| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Ziff Davis, Inc. (ZD) Q4 Revenue Slips to $406.7M as Net Income Declines | ||
| Mo | Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update | ||
| Mo | Wells Fargo Sees Amphastar Pharmaceuticals, Inc.'s (AMPH) AMP-007 as Key to Mid- to High-Single-Digit Growth | ||
| Mo | Marqeta, Inc. (MQ) Labeled 'Show-Me' Story After Q4 Report, Says Morgan Stanley | ||
| Mo | Willdan Group, Inc. (WLDN) Selected for $49M Energy Services Project at Mt. San Antonio College | ||
| Mo | The Marcus Corporation (MCS) Reports Improved Profitability for Fiscal 2025 | ||
| Mo | B. Riley Reduces Target Price on Shift4 Payments (FOUR) to $120, Post Q4 Earnings | ||
| Mo | B. Riley Cuts Target Price on Go Daddy (GDDY) to $215 | ||
| Mo | Mizuho Reduces Target Price on SM Energy (SM) to $31, Following Q4 Earnings Release | ||
| Mo | Benchmark Raises Target Price on Super Group (SGHC) to $18, Post Q4 Results | ||
| Mo | Barclays Cuts Target Price on United Wholesale Morgtage (UWMC) to $6 | ||
| Mo | RBC Capital Initiates Coverage on KKR & Co. Inc. (KKR) with an Outperform Call | ||
| Mo | Truist Reduces Target Price on Salesforce (CRM) to $280, Citing Sector-Wide Valuation Compression | ||
| Mo | RBC Capital Reduces Target Price on Fidelity National Information Services (FIS) to $69 on Slight Q4 Earnings Miss | ||
| Mo | Wells Fargo Trims Equitable Holdings (EQH) to $57 | ||
| Mo | Stifel Trims Target Price on DNOW In (DNOW) to $16, Due to ERP Risk | ||
| Mo | 12 Best-Performing S&P 500 Stocks in the Last 10 Years | ||
| Mo | Revolution Medicines, Inc. (RVMD) Net Loss Widens amid Progress on Clinical Trial Programs | ||
| Mo | Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials | ||
| Mo | Guardant Health, Inc. (GH) Strengthens Health Technology Portfolio with MetaSight Diagnostics Acquisition | ||
| Mo | Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval | ||
| Mo | Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development | ||
| Mo | Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs | ||
| Mo | Schrödinger, Inc. (SDGR) Transition to Licensing Model Triggers Robust Revenue Growth | ||
| Mo | Nuvation Bio Inc. (NUVB) Amends Protocol on Safusidenib Trials in Astrocytoma |